Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marius E Kraenzlin

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Nature Clinical Practice. Endocrinology & Metabolism|August 19, 2007
Does continued alendronate therapy improve bone mineral density and reduce fracture risk in postmenopausal women?Marius E Kraenzlin, Christian Meier
Therapeutische Umschau. Revue Therapeutique|March 10, 2012
[Osteoporosis: evaluation, diagnosis and monitoring]Christian Meier, Marius E Kraenzlin
Expert Opinion on Biological Therapy|January 27, 2006
Use of recombinant human thyroid-stimulating hormone in the management of well-differentiated thyroid cancerMarius E Kraenzlin, Christian Meier
Nature Reviews. Endocrinology|July 14, 2011
Parathyroid hormone analogues in the treatment of osteoporosisMarius E Kraenzlin, Christian Meier
Therapeutic Advances in Musculoskeletal Disease|August 8, 2012
Antiepileptics and bone healthChristian Meier, Marius E Kraenzlin
Revue Medicale De La Suisse Romande|October 3, 2002
[Diagnosis of osteoporosis]Marius E Kraenzlin, René Rizzoli, Peter Burckhardt
Therapeutische Umschau. Revue Therapeutique|September 16, 2008
[Laboratory assessment of osteoporosis]Marius E Kraenzlin, Markus Anliker, Andrea Griesmacher
Current Osteoporosis Reports|October 7, 2016
Effects of Incretin-Based Therapies and SGLT2 Inhibitors on Skeletal HealthAndrea Egger, Marius E Kraenzlin, Christian Meier
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 14, 2009
Use of bone turnover markers in the real world: are we there yet?Christian Meier, Markus J Seibel, Marius E Kraenzlin
Therapeutische Umschau. Revue Therapeutique|June 10, 2011
[Primary hyperparathyroidism]Isabelle Suter-Widmer, Marius E Kraenzlin, Christian Meier
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Nature Clinical Practice. Endocrinology & Metabolism|August 19, 2007
Does continued alendronate therapy improve bone mineral density and reduce fracture risk in postmenopausal women?Marius E Kraenzlin, Christian Meier
Therapeutische Umschau. Revue Therapeutique|March 10, 2012
[Osteoporosis: evaluation, diagnosis and monitoring]Christian Meier, Marius E Kraenzlin
Expert Opinion on Biological Therapy|January 27, 2006
Use of recombinant human thyroid-stimulating hormone in the management of well-differentiated thyroid cancerMarius E Kraenzlin, Christian Meier
Nature Reviews. Endocrinology|July 14, 2011
Parathyroid hormone analogues in the treatment of osteoporosisMarius E Kraenzlin, Christian Meier
Therapeutic Advances in Musculoskeletal Disease|August 8, 2012
Antiepileptics and bone healthChristian Meier, Marius E Kraenzlin
Revue Medicale De La Suisse Romande|October 3, 2002
[Diagnosis of osteoporosis]Marius E Kraenzlin, René Rizzoli, Peter Burckhardt
Therapeutische Umschau. Revue Therapeutique|September 16, 2008
[Laboratory assessment of osteoporosis]Marius E Kraenzlin, Markus Anliker, Andrea Griesmacher
Current Osteoporosis Reports|October 7, 2016
Effects of Incretin-Based Therapies and SGLT2 Inhibitors on Skeletal HealthAndrea Egger, Marius E Kraenzlin, Christian Meier
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 14, 2009
Use of bone turnover markers in the real world: are we there yet?Christian Meier, Markus J Seibel, Marius E Kraenzlin
Therapeutische Umschau. Revue Therapeutique|June 10, 2011
[Primary hyperparathyroidism]Isabelle Suter-Widmer, Marius E Kraenzlin, Christian Meier
Pageof 3